The ALS Association recently pledged a $2 million contribution aimed at augmenting the work of its ALS ONE-Massachusetts ALS Partnership (MAP), a new coalition of four aligned specialty health care organizations.
Embarking on a pioneering clinical trial, researchers at Los Angeles-based Cedars-Sinai Medical Center recently obtained authorization from the U.S. Food and Drug Administration (FDA) to test a new therapeutic approach to amyotrophic lateral sclerosis (ALS).
The ALS Association, LAS Finding a Cure and Massachusetts General Hospital recently invested approximately $3.6 million to broaden the NeuroBANK program, which offers core and infrastructure services to ALS research communities.
The ALS Association and Cytokinetics Inc. recently announced that they have chosen to continue and broaden their current partnership against ALS, furthering their support of various initiatives and programs.
Thanks to donations from the ALS Association’s ALS Ice Bucket Challenge, scientists have made significant progress in Project MinE’s worldwide gene sequencing work, identifying NEK1 as the new ALS gene.
The ALS Association and its Neuro Collaborative initiative have furthered their understanding of cellular amyotrophic lateral sclerosis (ALS) models, claiming that these models need to be aged before they can be used as new cell models.
Leaders at miRagen Therapeutics Inc., a clinical-stage biopharmaceutical company that creates novel microRNA-based therapeutics, recently received the first portion of a Translational Research Advancing Therapy for ALS (TREAT ALS) grant.
Leaders at the annual meeting of the American Academy of Neurology recently announced some important progress that has been made with regard to understanding and treating amyotrophic lateral sclerosis (ALS).
The ALS Association and Quantum Rehab, the world’s leading producer of complicated rehab power wheelchairs, have chosen to continue their partnership for providing premier-level services to people and families affected by ALS.
The ALS Association recently published a new report, called 'Medicines in Development for Rare Diseases,' to show that U.S. biopharmaceutical research companies are working hard to create new medicines for rare diseases.